Market Overview

Teva Announces Launch of Generic Symbyax in the United States

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax®. Symbyax® is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of approximately $82 million in the United States, based on IMS sales data.

Posted-In: News FDA

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters